

16085 U.S. PTO  
111203

Please type a plus sign (+) inside this box ☐

Attorney Docket P5032R1  
PATENT

EV 351 932 619 US: Express Mail Number

November 13, 2003: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

16085 U.S. PTO  
10/712892  
111203

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi J. Ashkenazi, San Mateo, CA  
Gretchen Frantz, San Francisco, CA  
Audrey Goddard, San Francisco, CA  
Lino Gonzalez, Hollister, CA  
Austin L. Gurney, Belmont, CA  
Paul Polakis, Burlingame, CA  
Andrew Polson, San Francisco, CA  
William I. Wood, Hillsborough, CA  
Thomas D. Wu, San Francisco, CA  
Zemin Zhang, Foster City, CA

Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

**1. Type of Application**

- [ ] This application is for an original, non-provisional application.
- [X] This is a non-provisional application claiming priority to provisional application no. 60/426,847, filed November 15, 2002, provisional no. 60/431,250, filed December 6, 2002, and provisional no. 60/437,344, filed December 31, 2002, the entire disclosures of which are hereby incorporated by reference.
- [ ] This is a [ ] continuation-in-part [ ] continuation [ ] divisional application claiming priority to application Serial Number \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

133 pages of specification  
2 pages of claims  
1 page(s) of abstract  
47 sheet(s) of drawings  
[x] formal [ ] informal

**3. Declaration or Oath**

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*

  X   An executed declaration of the inventor(s) ☐ is enclosed ☒ will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*

       A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*

       A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

*(for new and CIP applications)*

  X   An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☒ will follow.

*(for cont./div.)*

       The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

       Cancel in this application original claims \_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

       A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**6. Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	20	- 20 =	0	X \$18.00	\$0.00
Independent Claims	2	- 3 =	0	X \$86.00	\$0.00
Multiple dependent claim(s), if any				+ \$290.00	\$0.00
Filing Fee Calculation					\$770.00

**7. Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$.  
**A duplicate copy of this transmittal is enclosed.**

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**

**9. Additional Papers Enclosed**

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Application Data Sheet and Postcard.

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: Mark T. Kresnak, Ph.D.  
Customer No: 09157

Respectfully submitted,  
GENENTECH, INC.

By: 

Mark T. Kresnak, Ph.D.  
Reg. No. 42,767  
Telephone No. (650) 225-4461

Date: November 13, 2003

**CUSTOMER NO: 09157**